Biomarin
BioMarin develops and commercialises innovative biopharmaceuticals for rare diseases driven by genetic causes.
Financial Data
-
31st Dec 17 Source: CRO
- €491.6 million turnover
-
€1 million
profit - 300 employees
-
31st Dec 16 Source: CRO
- €377.3 million turnover
-
€0.1 million
profit - 236 employees
- 2 more years available »
Ranking
By Turnover
(€491.6 million)- 159th in Top Companies
- 23rd in Health
By Employees
(300)- 477th in Top Companies
- 69th in Health
- 300
- €491.6 million
Employees
- Michael O’Donnell CEO/Managing Director